Comparison of liver function tests between different genotypes of HBV and HCV in non-responders of HBV-HCVCo-infected patients with healthy controls
Paper Details
Comparison of liver function tests between different genotypes of HBV and HCV in non-responders of HBV-HCVCo-infected patients with healthy controls
Abstract
Hepatitis B and C co-infection may leads to cirrhosis resulting in hepatocellular carcinoma with poorer survival rate. Pegylated interferon and ribavirin treatment is considered as gold standard. Despite of adequate treatment, some patients remained non-responders. Due to this reason, this study was designed to compare different parameters of liver function tests along with HBV- HCV genotyping in non-responders of HBV-HCV co-infection with normal controls. Study population was divided in two groups. Group A (patient group) includes 30 HBV-HCV co-infected patients and Group B (control group).includes 30 normal individuals. Blood samples of both groups were collected. Samples were analyzed for HBV and HCV genotyping using automated kits of Abbott laboratories and Liver Functions testing (ALT, ALP, Bilirubin, Albumin) using ROCHE COBAS-501 automated system. Statistical analysis using chi-square test for ordinal data and t-test for numerical data was used using p-value <0.05 as significant. In all patients, HCV genotype was ‘3’. Most were co-infected with HBV genotype B (73.3%) as compared to genotype C (26.6%). Male to female ratio was about 1:1.1 in control group as compared to 6.5:1 in patients group. Mean age of controls was younger (32.3±6.8 years) as compared to patients (36.85±9.6 years).Overall, liver function tests were significantly high in patients group (p-value <0.05) as compared to controls. However, albumin and alkaline phosphatase levels show insignificant difference in HBV Genotype B and C patients. In conclusion, HBV-HCV co-infected patients have higher mean age, mean values of different parameters of liver function tests were significantly high in patient group as compared to control group.
Ahmad B, Ali S, Ali I, Azam S, Bashir S. 2012. Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Journal of Virology 9, 1-4.
Bartosch Cosset FL. 2006.Cell entry of hepatitis C virus. Virology 348, 1-12.
Biliotti E, Kondili LA, Furlan C, Ferretti G, Zacharia S, DeAngelis M, Guidu S, Gusman N, Taliani G. 2008. Acute hepatitis B in patients with or without underlying chronic HCV infection. Journal of Infection 57, 152-157.
Bini EJ, Perumals WPV. 2010. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences and viral interactions. Hepatology 51, 759-766.
Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE. 2004. Peg interferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-co-infected persons. New England Journal of Medicine 351, 451-459.
Crockett SD, Keeffe EB. 2005. Natural history and treatment of hepatitis B virus and hepatitis C virus co-infection. Annals of Clinical Microbiology and Antimicrobial 4, 13.
Datta S, Chatterjee S, Veer V, Chakravarty R. 2012. Molecular biology of the hepatitis B virus for clinicians. Journal of Clinical and Experimental Hepatology 2, 353-365.
Karoney MJ, Siika AM. 2013. Hepatitis C virus (HCV) infection in Africa: a review. Pan Africa Medical Journal, 14-44.
Lee JP, Dai CY, Chuang WL, Chang WY, Hou NJ, Hseih MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chen TJ, Yu ML. 2007. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C coinfected patients. Journal of Gastroenterology and Hepatology 22, 515-517.
Liu Z, Hou J. 2006. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. International Journal of Medical Science 3, 57-62.
Mitre HP, Mendonça JSD. 2007. Co-infection with hepatitis B virus and hepatitis C virus. Brazilian Journal of Infectious Diseases 11, 33-35.
Neuveut C, Wei Y, Buendia MA. 2010. Mechanisms of HBV-related hepatocarcinogenesis. Journal of Hepatology 52, 594-604.
Pan Y, Wei W, Kang L, Wang Z, Fang J, Zhu Y, Wu J. 2007. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochemical and Biophysical Research Communications 359, 70-75.
Sagnelli E, Coppola N, Pisaturo M, Masiekko A, Tonziello G, Sagnelli C, Messina V, Filippini P. 2009. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 49, 1090- 1097.
Williams R. 2006. Global challenges in liver disease. Hepatology 44, 521-526.
Naveeda Manzoor, Kirn-e-Muneera, Muhammad Adnan S, Naseer Ahmed, Shazia Fatima, 2018. Comparison of liver function tests between different genotypes of HBV and HCV in non-responders of HBV-HCVCo-infected patients with healthy controls. Int. J. Biosci., 13(3), 68-74.
Copyright © 2018 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.